Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) EPS (Basic) (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EPS (Basic) for 15 consecutive years, with -$0.04 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 89.19% to -$0.04 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.7, a 23.08% increase, with the full-year FY2024 number at -$1.95, up 54.01% from a year prior.
  • EPS (Basic) was -$0.04 for Q3 2025 at Plus Therapeutics, down from $0.02 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.02 in Q2 2025 to a low of -$3.29 in Q3 2022.
  • A 5-year average of -$0.8 and a median of -$0.47 in 2024 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): plummeted 1075.28% in 2022, then surged 104.44% in 2025.
  • Plus Therapeutics' EPS (Basic) stood at -$0.28 in 2021, then crashed by 742.86% to -$2.36 in 2022, then surged by 72.88% to -$0.64 in 2023, then increased by 23.44% to -$0.49 in 2024, then soared by 91.84% to -$0.04 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's EPS (Basic) are -$0.04 (Q3 2025), $0.02 (Q2 2025), and -$1.19 (Q1 2025).